Manufacturers Support CMS’ New TAVR National Coverage Decision
Executive Summary
CMS has completed its new national Medicare Coverage with Evidence Development policy for transcatheter aortic valve replacement. The final decision memo largely maintains the recommendations from the draft version released in March, including more flexible criteria for centers establishing TAVR programs, while emphasizing the importance of the interdisciplinary heart team for decision-making about valve replacement.
You may also be interested in...
Exec Chat: Medtronic’s Goodheart Talks About COVID, AI, Diversity, TAVR And More
Medtech Insight sat down with Nina Goodheart, the president of Medtronic’s structural heart and aortic operating unit, to learn more about her experience with the company during the pandemic, the company’s commitment to diversity and inclusion, and the future of structural heart technology.
CMS Proposes Coverage Policy For Transcatheter Edge-to-Edge Mitral Valve Repair
In a new draft National Coverage Determination, the US Medicare agency proposes extending coverage of transcatheter mitral valve repair to certain patients with functional mitral regurgitation.
Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations
Sales of Sapien transcatheter aortic valves grew about 27% year over year in the third quarter of 2019 while revenues from Edwards’ transcatheter mitral and tricuspid therapies grew to almost $10m, led by sales of the Pascal transcatheter mitral repair system in Europe.